title: Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
authors.affiliation: Harvard Radiation Oncology Program, Boston, MA, USA.
authors.forename: Justin C
authors.initials: JC
authors.lastname: Voog
authors.affiliation: NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Paulus
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA,. Electronic address: jefstathiou@partners.org.
authors.forename: Jason A
authors.initials: JA
authors.lastname: Efstathiou
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms
chemical_list: D000726:Androgen Antagonists